Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers REGENXBIO’s quarter ended September 30, 2026.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers REGENXBIO’s quarter ended September 30, 2026
- Results of operations and financial condition details are in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and marketable securities $251.0M, plus $39.0M October settlement proceeds, funding operations into late Q4 2027
- Q3 revenue $9.2M vs $29.7M, reflecting $21.2M lower ZOLGENSMA royalties after U.S. patent expiration
- Net loss narrowed to $40.7M, or $0.62 per share, from $61.9M, or $1.20, helped by a $38.0M litigation gain
- RGX-202 BLA submission remains targeted for Q1 2027, with potential accelerated approval in 2H 2027
- ATMOSPHERE and ASCENT wet AMD topline data expected in Q4 2026, a major near-term clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.